ATE186464T1 - Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur'' - Google Patents

Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur''

Info

Publication number
ATE186464T1
ATE186464T1 AT91911934T AT91911934T ATE186464T1 AT E186464 T1 ATE186464 T1 AT E186464T1 AT 91911934 T AT91911934 T AT 91911934T AT 91911934 T AT91911934 T AT 91911934T AT E186464 T1 ATE186464 T1 AT E186464T1
Authority
AT
Austria
Prior art keywords
rns
cap structure
methods
regulating
altering
Prior art date
Application number
AT91911934T
Other languages
English (en)
Inventor
Brenda F Baker
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE186464T1 publication Critical patent/ATE186464T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT91911934T 1990-05-23 1991-05-22 Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur'' ATE186464T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23

Publications (1)

Publication Number Publication Date
ATE186464T1 true ATE186464T1 (de) 1999-11-15

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91911934T ATE186464T1 (de) 1990-05-23 1991-05-22 Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur''

Country Status (15)

Country Link
EP (1) EP0531447B1 (de)
JP (1) JPH06500075A (de)
KR (1) KR960004931B1 (de)
AT (1) ATE186464T1 (de)
AU (1) AU649458B2 (de)
BR (1) BR9106486A (de)
CA (1) CA2083377C (de)
DE (1) DE69131773T2 (de)
DK (1) DK0531447T3 (de)
ES (1) ES2139578T3 (de)
FI (1) FI925210L (de)
GR (1) GR3032457T3 (de)
HU (1) HUT63568A (de)
NO (1) NO924309L (de)
WO (1) WO1991017755A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
DE69430740T2 (de) * 1993-04-01 2003-02-06 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
AU2001239856A1 (en) * 2000-02-25 2001-09-03 Tao Biosciences, Llc Platform for the discovery of the bacterial genes involved in rna modification
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (de) 2009-07-06 2013-05-29 Ontorii Inc Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
EP3095459A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
EP3094728B1 (de) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chirales design

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
KR927003044A (ko) * 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법

Also Published As

Publication number Publication date
HUT63568A (en) 1993-09-28
CA2083377A1 (en) 1991-11-24
WO1991017755A1 (en) 1991-11-28
FI925210A7 (fi) 1992-11-17
JPH06500075A (ja) 1994-01-06
NO924309D0 (no) 1992-11-09
EP0531447A4 (en) 1993-08-11
KR960004931B1 (ko) 1996-04-18
DK0531447T3 (da) 2000-03-27
HU9203659D0 (en) 1993-04-28
CA2083377C (en) 2002-11-26
DE69131773D1 (de) 1999-12-16
AU8080291A (en) 1991-12-10
EP0531447B1 (de) 1999-11-10
AU649458B2 (en) 1994-05-26
EP0531447A1 (de) 1993-03-17
FI925210A0 (fi) 1992-11-17
KR930700118A (ko) 1993-03-13
ES2139578T3 (es) 2000-02-16
DE69131773T2 (de) 2000-03-02
GR3032457T3 (en) 2000-05-31
FI925210L (fi) 1992-11-17
NO924309L (no) 1992-11-09
BR9106486A (pt) 1993-05-25

Similar Documents

Publication Publication Date Title
DE69131773D1 (de) Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur"
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
DE69433626D1 (de) N-2 substituierte purine
PL334530A1 (en) Novel genes specific in respect to n-axecetyl-l-phosphotricin, used to code amino acids deacetylase, their isolation and application
ATE292141T1 (de) Oligoribonukleotide und ribonucleasen zur spaltung von rns
MX9602993A (es) Hormona del crecimiento humano.
BR9105935A (pt) Composicao,analogo de oligonucleotideo,oligonucleotideo sequenciado misto,processo para a preparacao de nucleosideos 2'-substituidos,composicao para modular a atividade de rna,processos para modular a producao de uma proteina por um organismo,para tratar um animal,para detectar a presenca ou ausencia de rna,oligonucleotideo ou analogo de analogo de oligonucleotideo resistente a nuclease e processo para tratar um organismo tendo uma doenca
ATE230439T1 (de) Gezielte gentherapie
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
ATE267247T1 (de) Reagenz und verfahren zur inhibierung der n-ras expression
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69032080D1 (de) Verwendung von konservierten Oligonukleotid-Primern zur Amplifizierung von menschlichen Papillomavirus-DNS-Sequenzen
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
BR1100617A (pt) Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
SE7706425L (sv) Forfarande for framstellning av polyribonukleotider med aktivitet vid alstrandet av leukocyter och blodplettar
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
Dawid et al. Gene expression in amphibian embryogenesis
FR2617403B1 (fr) Procede de preparation de derives des acides nucleiques et procede de preparation d'une composition medicale les contenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee